Stock search

Ticker or company name

BIIB card

BIIB price forecast

Biogen$251,65

P/E now is 108,5. Average over 5 years: 22,0 (range 14–23). The stock is 392% above its history.

Base · FY2030

$205,19−4,8% a year

The base case gives −4,8% a year, below your target of 10%.

Settings

%

No analyst consensus: assumptions come from the company's last 5 years. Change any in the table.

Assumptions by year

FY2026FY2027FY2028FY2029FY2030
Revenue growth, %
Net margin, %
Change in shares, %
Payout ratio, %
P/E low
P/E base
P/E high
Revenue$9,30 bn$8,75 bn$8,23 bn$7,74 bn$7,28 bn
Net income$1,60 bn$1,50 bn$1,41 bn$1,33 bn$1,25 bn
EPS$11,06$10,60$10,15$9,72$9,31

Changed values are highlighted. Bear and bull cases: growth ∓ 7,9%, margin ∓ 2 pp, low and high P/E.

Price at year end

  • Base
  • Bear – Bull
  • now $251,65

The dot is the base case, the line runs from bear to bull, the dashed line is today's price.

Result at the end of FY2030

Bear$74,08

Price change
−70,6%
A year
−25,7%
Fair value today
$50,03
Margin of safety
−80,1%

Base$205,19

Price change
−18,5%
A year
−4,8%
Fair value today
$138,56
Margin of safety
−44,9%

Bull$362,40

Price change
+44,0%
A year
+9,3%
Fair value today
$244,72
Margin of safety
−2,8%

What growth the price implies

For the stock to return 10% a year, revenue must grow 6% a year to FY2030 at a 17,2% margin and P/E 22,0.

Growth over 5 years
−6%
Analyst consensus
no data
In your model
−6%

Calculated from your assumptions. Not an investment recommendation.

Base · FY2030$205,19−4,8% a year